Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials (2008)

Peer-Reviewed Study · NSCLC Meta-Analyses Collaborative Group (Burdett S, Stephens R, Stewart L, Tierney J, et al.) · October 1, 2008

NSCLC Meta-Analyses Collaborative Group (Burdett S, 2008-10-01: Individual-patient-data meta-analysis of 16 RCTs (2,714 patients) comparing chemotherapy plus supportive care with supportive care alone in advanced NSCLC. Hazard ratio 0.77; 1-year survival rose from 20% to 29%; median survival rose 1.5 months, from 4.5 to 6 months.

an absolute improvement of 9% at 12 months increasing survival from 20% to 29% or an absolute increase in median survival of 1.5 months (from 4.5 months to 6 months)

Overall Survival (JCO 26:4619 approx.; HTML full text)

NSCLC Meta-Analyses Collaborative Group (Burdett S, 2008-10-01: Individual-patient-data meta-analysis of 16 RCTs (2,714 patients) comparing chemotherapy plus supportive care with supportive care alone in advanced NSCLC. Hazard ratio 0.77; 1-year survival rose from 20% to 29%; median survival rose 1.5 months, from 4.5 to 6 months. Funding: not stated in the PubMed record or the PMC text retrieved. COI: none captured. Comparator: supportive care alone (no chemotherapy). The authors' conclusion is strongly positive ('all patients who are fit enough and wish to receive chemotherapy should do so'), which cuts against a 'does not work' reading; the 1.5-month median gain cuts the other way on magnitude. 65% more data than the group's 1995 analysis; heterogeneity P=.02, I2=47%. Study type: review.